CLINICAL_TRIALS ClinicalTrials.gov record update

TRUDI: A Phase II Study of Neoadjuvant Trastuzumab Deruxtecan and Durvalumab for Stage III, HER2-expressing Inflammatory Breast Cancer

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT05795101
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-25T22:27:17.392840+00:00
Published At: 2025-09-19T00:00:00+00:00
Record Updated At: 2025-09-19
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Invasive Breast Cancer", "Inflammatory Breast Cancer Stage III", "HER2-positive Breast Cancer", "HER2 Low Breast Adenocarcinoma", "Breast Cancer"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2025-09-19"
protocolSection.identificationModule.nctId: "NCT05795101"
protocolSection.identificationModule.officialTitle: "TRUDI: A Phase II Study of Neoadjuvant Trastuzumab Deruxtecan and Durvalumab for Stage III, HER2-expressing Inflammatory Breast Cancer"
protocolSection.statusModule.overallStatus: "RECRUITING"
protocolSection.designModule.phases: ["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.